62nd ASH Annual Meeting and Exposition: Author Index N

N'guyen-Quoc, S.

140 - Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study

Nabergoj, M.

1493 - Impact of Different T Cell Depletion Protocols on Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation
2401 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT

Nabet, B.

950 - Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Nabhan, C.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Naccache, M.

3453 - The World Federation of Hemophilia Gene Therapy Registry

Nachabe, A.

102 - COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients

Nachar, V.

1146 - Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis

Nachmani, D.

2761 - Aberrant rRNA 2’-O-Methylation Causes Bone Marrow Failure and Defective Immune Function

Nachmias, B.

1873 - IPO11 Regulates the Nuclear Import of BZW1/2 and Is Necessary for AML Cells and Stem Cells
2141 - Rituximab, Methotrexate, Procarbazine and Lomustine (R-MPL) for the Treatment of Primary CNS Lymphoma
2899 - The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Nacionales, T.

865 - A Novel VWD Variant Identified in a Multi-Generational Canadian Ojibway Kindred with a Type 2B VWD Phenotypic Expression

Nacson, J.

1052 - TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Nadal, J. A.

2518 - Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review

Nadal Rios, R.

1531 - Rapid Engraftment, Immune Recovery, and Resolution of Transfusion Dependence in Treatment-Refractory Severe Aplastic Anemia Following Transplantation with Ex Vivo Expanded Umbilical Cord Blood (Omidubicel)

Nadarajah, N.

195 - Machine Learning (ML) Can Successfully Support Microscopic Differential Counts of Peripheral Blood Smears in a High Throughput Hematology Laboratory
360 - Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies
1558 - Employment of Machine Learning Models Yields Highly Accurate Hematological Disease Prediction from Raw Flow Cytometry Matrix Data without the Need for Visualization or Human Intervention
2180 - Cracking a Nut with a Sledgehammer? – Broadening the Spectrum of Gene Mutation Analysis in MDS Does Not Add Clinically Relevant Information
2470 - The Diverse Landscape of Fusion Transcripts in 25 Different Hematological Entities

Nadeem, O.

3197 - TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

Nadeem, O.

1398 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
1603 - Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM
2293 - HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—Age Subgroup Analysis of Elderly Patients
2321 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy—Subgroup Analysis
2564 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)—Analysis of Adverse Events Related to Hospitalizations
3214 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)—Subgroup Analysis
3237 - HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics—Subgroup Analysis
3477 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) — Health-Related Quality of Life (HRQoL) Analysis

Nadel, B.

281 - Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Nadella, S.

211 - Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison

Nademanee, A. P.

472 - Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma
533 - Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP
617 - Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Nadeu, F.

350 - The IGLV3-21^R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome
660 - The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL
1104 - Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

Nadler, P. I.

1254 - Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Nagai, M.

2336 - Mutated GM-CSF-Based CAR T-Cells Targeting CD116/CD131 Complexes Exhibit Enhanced Anti-Tumor Effects Against Acute Myeloid Leukemia

Nagai, Y.

1111 - Genomic Analysis of Diffuse Large B Cell Lymphoma in a Japanese Cohort Using Targeted DNA Sequencing
3170 - Single-Cell Analyses Unravel Unique Features of Plasma Cell Clones in POEMS Syndrome

Nagami, S.

1781 - An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Nagamuthu, C.

708 - Outcome Among Adolescents and Young Adults with Mature B-Cell Non Hodgkin Lymphoma at Pediatric Versus Adult Centers: A Population-Based Study Using the IMPACT Cohort
742 - Frailty Is Associated with Increased One-Year Mortality in Patients with Newly Diagnosed Diffuse Large-B-Cell Lymphoma: A Population-Based Study

Nagar, M.

1054 - A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Nagarajan, C.

3026 - Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide
3218 - Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) – Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Nagarakanti, S.

3464 - Association of Blood Type on Clinical Outcomes in Black/African Americans Hospitalized for COVID-19 Infection

Nagasawa, F.

2827 - Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia

Nagasawa, T.

925 - Impaired Osteoblastic Differentiation of MSCs Suppresses Normal Hematopoiesis in MDS

Nagata, Y.

3100 - Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA

Nagata, Y.

34 - The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia
288 - Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms
1866 - Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia
2187 - Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia

Nagle, S. J.

1149 - Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
3271 - Endothelial Injury Markers and Central Nervous System Damage-Associated Proteins in Immune Effector Cell-Associated Neurotoxicity Syndrome

Nagler, A.

79 - Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT
545 - Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia
562 - Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT
614 - Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
982 - Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol
1054 - A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia
1182 - CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma：a Safety and Efficacy Study
1749 - A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies
2425 - Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT
2429 - Impact of Donor Kinship on Non-T-Cell Depleted Haploidentical Stem Cell Transplantation (haploHCT) with Post Transplantation Cyclophosphamide (PTCy): From the ALWP of the EBMT
3344 - Outcomes of Hematopoietic Stem Cell Transplantation from Non T– Cell Depleted Haploidentical Versus Matched Sibling Donor in Adult Patients with Acute Lymphoblastic Leukemia in Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrowtransplantation
3355 - Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Nagler, E.

1822 - ABO/Rh Blood Group and COVID-19 Infection Severity

Nagovski, N.

3222 - Daratumumab Dose Analysis Among Patients with Multiple Myeloma in a US Community Oncology Setting: A Retrospective Observational Study in Integra Connect Network

Nagy, Z.

3021 - Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
3086 - Momelotinib’s Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia
3238 - Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Nahar, A.

374 - Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study
1158 - Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Nahas, M.

2103 - ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

Nahi, H.

144 - A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
180 - Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
3217 - Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Nahi, H.

2299 - Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Nahrendorf, M.

1843 - Reversing Clonal Hematopoiesis and Associated Atherosclerotic Disease By Targeted Antibody-Drug-Conjugate (ADC) Conditioning and Transplant

Nai, A.

220 - Transferrin Receptor 2 Is a Novel Target to Ameliorate Anemia of Chronic Kidney Disease
223 - FKBP12-Dependent Hepcidin Inhibition: Molecular Mechanism and Potential Therapeutic Implications

Naidoo, N.

994 - Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

Naidu, P.

657 - Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
2192 - Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Naik, A.

2984 - Prognostic Factors for North American Adult T Cell Leukemia Lymphoma: Defining Risk Groups Using a Four-Point Score Prognostic System
3484 - Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Naik, R. P.

1845 - JAK2 V617F Prevalence Study: Associations in the General Population and Vascular Disease Populations

Naik, S.

476 - Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era
705 - The Burkitt Lymphoma International Prognostic Index (BL-IPI)
706 - Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis
3051 - EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Naik, S.

609 - Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

Naim, A.

1422 - Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment
1488 - Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Nair, A. M.

1155 - A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Nair, B.

117 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
542 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Nair, G. B.

577 - Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients

Nair, P. R.

989 - Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01
2784 - Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01
2820 - Prediction of Clinical Response for Frontline Treatment of Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-02
2906 - Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-04

Nair, R.

2119 - Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy
2128 - Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
2983 - Association of Epstein–Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin’s Lymphoma
3046 - Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival
3308 - Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies
3340 - Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma

Nair, R.

645 - A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
1129 - Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients
1138 - Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma
1511 - Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience
2042 - Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial
2058 - Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma
2357 - Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma

Nair, R.

1171 - Adolescent and Young Adult Hodgkin Lymphoma: Is More Better?

Nair, S. M.

1715 - Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study

Nair, S.

3378 - Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer

Najera Irazu, M. J.

2805 - Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Najima, Y.

1478 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)

Najman, L.

1712 - Outcome of Severe Vaso-Occlusive Crisis in Sickle Cell Disease Adults Admitted to Referral Centers in Africa and Europe. Introduction of Machine Learning Methods to Improve the Presev Score

Najmuddin, M. M.

2382 - Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review

Nakafeero, M.

2620 - Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience

Nakagawa, M. M.

1268 - Functional Characterization of Compound DDX41 Germline and Somatic R525H Mutations in the Development of Myeloid Malignancies
1842 - Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method
1866 - Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia
2898 - Analysis of Clonal Evolution of AML Using Simultaneous Single-Cell DNA/RNA Analysis

Nakahara, F.

1634 - Predictors of Glucocorticoid Responsiveness in Multicentric Castleman’s Disease
1829 - CD62L Expression Level Dictates the Cell Fate of Myeloid Progenitors in Mice and Humans

Nakajima-Takagi, Y.

1874 - Immunoglobulin Superfamily Member 8 Is Indispensable for Myeloid Leukemia Via Wnt/β-Catenin Signaling Pathway

Nakamae, H.

1532 - Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Nakamae, M.

1532 - Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Nakamura, A.

1406 - Synergistic Effect of Venetoclax for Antibody Dependent Cell Cytotoxicity By Daratumumab

Nakamura, F.

2827 - Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia

Nakamura, K.

SCI-39 - The Immune System and Progression from Precursor Condition to Active Myeloma

Nakamura, M.

1031 - Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Nakamura, M.

980 - Prognostic Analyses for Adult Relapsed / Refractory Acute Lymphoblastic Leukemia Patients Who Received First Allogenic Hematopoietic Stem Cell Transplantation

Nakamura, R.

3213 - Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Nakamura, R.

75 - A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
192 - Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)
298 - Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial
617 - Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"
991 - Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)
1464 - Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization
1470 - Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis
1482 - Vaccination of Hematopoietic Stem Cell (HCT) Donors with Triplex, a Novel Cytomegalovirus Vaccine: Safety, Feasibility and Adoptive Transfer of Protective CMV-Specific T Cells in HCT Recipients
1520 - Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR
3345 - Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis
3351 - Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases
3357 - Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Nakamura, Y.

2827 - Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia

Nakamura, Y.

768 - Transcriptional Regulation of Ferroptosis in X-Linked Sideroblastic Anemia
1703 - Catalytic Activity of Heme-Regulated eIF2 Alpha Kinase (HRI) Regulates Fetal Hemoglobin
2608 - Genetic Silencing of KEAP1 Induces NRF2 Mediated Oxidative Stress Pathway in Human Erythroid Cells

Nakamura, Y.

2827 - Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia

Nakane, T.

1532 - Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Nakano, H.

1425 - Dimethyl Fumarate Ameliorates Graft-Versus-Host Disease By Negatively Regulating Aerobic Glycolysis in Alloreactive T-Cells

Nakano, T. A.

254 - Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome
1667 - A Pilot Review of Outcomes in Pediatric MDS: Validating Methods for a North American Multicenter Study

Nakao, S.

258 - Clonal Hematopoiesis By HLA Class I Allele-Lacking Hematopoietic Stem Cells and Concomitant Aberrant Stem Cells Is Rarely Associated with Clonal Evolution to Secondary Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Acquired Aplastic Anemia
933 - Epigenetic Loss of the HLA-DR15 Expression on Hematopoietic Stem Progenitor Cells in Patients with Acquired Aplastic Anemia Characterized By Cyclosporine Dependency: A Novel Mechanism Underlying the Immune Escape of Hematopoietic Stem Progenitor Cells
3174 - Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) Vs. Next-Generation Sequencing

Nakar, C.

1779 - Plasminogen Eye Drops Are Effective in Preventing Recurrence of Pseudomembranes in Ligneous Conjunctivitis: Results from the Phase 2/3 KB046 Trial
1799 - Acute Airway Obstruction in 4 Pediatric Patients with Congenital Plasminogen Deficiency (C-PLGD) Treated with Intravenous Plasminogen (Human) Replacement Therapy Under an Expanded Access Protocol

Nakaseko, C.

45 - Nilotinib Vs. Dasatinib in Achieving MR^4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212
1111 - Genomic Analysis of Diffuse Large B Cell Lymphoma in a Japanese Cohort Using Targeted DNA Sequencing
1478 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
3170 - Single-Cell Analyses Unravel Unique Features of Plasma Cell Clones in POEMS Syndrome
3174 - Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) Vs. Next-Generation Sequencing

Nakashima, I.

1019 - Tumor-Tropic Liposome-Mediated Therapeutic Delivery of mRNA for T Cell Malignancies
2336 - Mutated GM-CSF-Based CAR T-Cells Targeting CD116/CD131 Complexes Exhibit Enhanced Anti-Tumor Effects Against Acute Myeloid Leukemia

Nakashima, Y.

1532 - Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Nakasone, H.

1478 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)

Nakatani, K.

35 - KRAS mutations Frequently Coexist with High-Risk MLL Fusions and Are Independent Adverse Prognostic Factors in MLL-Rearranged Acute Myeloid Leukemia
1046 - Autophagy Inhibition Enhances CDK4/6 Inhibitor-Induced Apoptosis in t(8;21) Acute Myeloid Leukemia Cells

Nakauchi, H.

1851 - SATB1 Regulates GATA1 Protein Expression in Early Hematopoiesis and Is Deregulated in Diamond Blackfan Anemia

Nakauchi, Y.

325 - Cytokine Rescue and Targeting of Inflammation-Sensitive RUNX1 Deficient Human CD34⁺ Hematopoietic Stem and Progenitor Cells

Nakayama, H.

2014 - Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity

Nakayama, M.

1268 - Functional Characterization of Compound DDX41 Germline and Somatic R525H Mutations in the Development of Myeloid Malignancies

Nakazaki, K.

1924 - Early Death in Patients with Disseminated Intravascular Coagulation during Induction Therapy for Acute Promyelocytic Leukemia: A Nationwide Analysis

Nakazawa, H.

1125 - Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma
1866 - Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia

Nakazawa, Y.

1019 - Tumor-Tropic Liposome-Mediated Therapeutic Delivery of mRNA for T Cell Malignancies
2014 - Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity
2336 - Mutated GM-CSF-Based CAR T-Cells Targeting CD116/CD131 Complexes Exhibit Enhanced Anti-Tumor Effects Against Acute Myeloid Leukemia

Nakhoda, S.

478 - CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Nakitandwe, J.

1996 - Genomic Analysis of Congenital Myeloid Sarcoma Identifies Significant Bone Marrow Involvement in the Absence of Morphologic Blasts

Nalawade, S. S.

2123 - A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma (PCNSL)

Nall, S.

188 - Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Nam, A. S.

107 - Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation
348 - Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK^C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia
- Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation
- Live Q&A

Nam, H.

1303 - Accessing Genomic Alternations in Chronic Lymphocytic Leukemia Using an NGS-Based Comprehensive Genomic Profiling Assay
3379 - A Novel Multimodal Next Generation Sequencing Assay with Total Nucleic Acid Input to Provide Comprehensive Genomic Profiling for Hematologic Malignancies

Nam, K. Y.

3376 - PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Nam, S.

2868 - Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Namazzi, R.

2488 - Impact of a National Lockdown for COVID-19 on Morbidity and Mortality Among Children with Sickle Cell Anaemia at a Tertiary Care Hospital in Uganda

Namini, H.

134 - Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Nammacher, K.

2471 - Addressing Discordant Perceptions and Beliefs between Patients with Hemophilia and Their Care Teams: Results from a Pilot Program to Build Skills in Shared Decision-Making

Nampoothiri, R. V.

1565 - Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre – a Prospective Observational Study
3316 - Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Nan, F.

973 - First-in-Class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Nana, R.

3123 - Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

Nanaa, A.

3123 - Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

Nanayakkara, D.

1464 - Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization

Nancy, C.

1165 - Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
2121 - Proposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL)
2960 - Follicular Lymphoma in Latin America: Real-World Experience from 763 Patients
2968 - Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
3036 - COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study

Nand, S.

205 - Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Nandakumar, B.

2280 - Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
3160 - Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)

Nandakumar, S.

129 - Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Nangalia, J.

LBA-1 - Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms

Nanni, C.

3326 - Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial

Nanni, J.

1927 - A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice
2889 - A Three-Gene Immune Signature Including IDO1, BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

Nanni, M.

3129 - Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System
3142 - Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas’

Nanno, S.

1532 - Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Nannya, Y.

35 - KRAS mutations Frequently Coexist with High-Risk MLL Fusions and Are Independent Adverse Prognostic Factors in MLL-Rearranged Acute Myeloid Leukemia
288 - Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms
385 - Combined Landscape of Gene Mutations and Copy Number Alterations in Clonal Hematopoiesis: Analysis in 10,612 Japanese Individuals
709 - Prognostic Relevance of Genetic Abnormalities in Blastic Transformation of Chronic Myeloid Leukemia
1268 - Functional Characterization of Compound DDX41 Germline and Somatic R525H Mutations in the Development of Myeloid Malignancies
1842 - Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method
1866 - Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia
2898 - Analysis of Clonal Evolution of AML Using Simultaneous Single-Cell DNA/RNA Analysis
3125 - ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Nanwani, K.

858 - Study of the Effect of Fibrinogen, Factor XIII and Recombinant Activated Factor VII in a Model of Trauma-Induced Coagulopathy

Naoe, T.

27 - Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3^mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy
45 - Nilotinib Vs. Dasatinib in Achieving MR^4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Naparstek, J.

3272 - Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Napier, E.

1200 - Ibrutinib before Apheresis May Improve Tisagenlecleucel Manufacturing in Relapsed/Refractory Adult Diffuse Large B-Cell Lymphoma: Initial Results from a Phase 1b Study

Napolitano, S.

741 - Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Naqvi, K.

1242 - Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia
1281 - AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis
1288 - Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
1289 - Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
2147 - Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia
2150 - The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis
2189 - Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation
2203 - A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
3067 - Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure
3071 - Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia
3116 - Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)
3120 - Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

Narahari, P.

3394 - Optimizing Pain Management for Children with Sickle Cell Disease Vaso-Occlusive Crisis in the Emergency Department

Narang, J.

2227 - The Clinical Relevance of Residual, Persistent and Elongated Abnormal Sized Nodes By Longest Diameter (LDi) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL), Otherwise in a Complete Remission (CR)

Narang, M.

3244 - Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect^® MM Registry

Narayan, R.

657 - Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
1952 - A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies
2192 - Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose
2402 - A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation

Narayan, R.

1955 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Narayanan, S.

342 - Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms – Results of the Tamarin Study
1250 - Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Narcisse, N.

426 - Effect of Sutimlimab Treatment on Healthcare Resource Utilization in Patients with Cold Agglutinin Disease

Nardi, V.

445 - Rare Inherited Defects of the Complement System in Purpura Fulminans
1259 - Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk

Nardo, L.

LBA-5 - ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Narendran, A.

1975 - A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children

Naresh, K.

2749 - Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia

Narita, A.

2757 - Diagnostic Whole Exome Sequencing for 166 Patients with Inherited Bone Marrow Failure Syndrome

Narita, K.

2757 - Diagnostic Whole Exome Sequencing for 166 Patients with Inherited Bone Marrow Failure Syndrome

Narita, M.

1426 - Genetic Manipulation Resulting in Decreased Donor Chondroitin sulfate Synthesis Mitigates Gvhd Following Allogeneic Hematopoietic Cell Transplantation in a Murine Model.

Narla, A.

1851 - SATB1 Regulates GATA1 Protein Expression in Early Hematopoiesis and Is Deregulated in Diamond Blackfan Anemia
1853 - Targeting of Calbindin 1 (CALB1) Rescues Erythropoiesis in a Human Model of Diamond Blackfan Anemia: Implications for Novel Therapies
2755 - Metformin Upregulates Mir-26a to Improve Erythropoiesis in Preclinical Models of Diamond Blackfan Anemia through Suppression of Nlk Expression

Narla, G.

966 - Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Narla, M.

84 - The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis
224 - Fetal Hemoglobin Rescues Ineffective Erythropoiesis in Sickle Cell Disease

Narni, F.

141 - Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial

Nartea, M. E.

2964 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Naruse, K.

2741 - The Expression and Role of Multiple Forms of Granulocyte Colony-Stimulating Factor in Medaka Fish

Naruto, T.

2014 - Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity

Narvekar, Y.

989 - Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01

Nasa, P.

1624 - Outcomes in Vaso-Occlusive Crisis Treatment in the Emergency Department Vs. Acute Care Observation Center

Nasamran, C. A.

232 - Lymphatic Remodeling Associated with Hemophilic Joint Bleeding in FVIII-Deficient Mice

Naseem, S.

2012 - “Detection of BCR-ABL1-like Subtype in Adult Acute Lymphoblastic Leukemia Using Digital Ncounter Nanostring Technology”

Nash, M.

935 - Clonal Hematopoiesis in Patients with Diamond Blackfan Anemia

Nashed, J.

357 - Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study
3317 - Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Nasir, S.

623 - Factors Predictive of Oral Abstract Being Published: Is Gender Disparity Playing a Role?

Nasnas, P.

1236 - Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors
1239 - Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib
1934 - Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study
1939 - Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
3070 - Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors

Nasr, M.

533 - Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Nasri, M.

682 - Efficient Correction of HAX1 Mutations in Primary HSPCs of Severe Congenital Neutropenia Patients Using CRISPR/CAS9 GENE-Editing
684 - Transcriptome Analysis of Severe Congenital Neutropenia Associated Leukemia with Different Types of RUNX1 Mutations in an iPSC-Based Model

Nasser, J. M.

1436 - Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment
3257 - Generation of Natural Killer Cells with Enhanced Function from a CRISPR/Cas12a-Edited Induced Pluripotent Stem Cell Line

Nasso, D.

1164 - Antiemetic Prophylaxis with NEPA (NETUPITANT/PALONOSETRON) and Dexamethasone to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) in Hodgkin’S Lymphoma Naïve Patients Receiving ABVD Regimen: A Multicenter Phase Iia Study

Nasta, S.

1658 - Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease

Nastoupil, L. J.

645 - A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
702 - Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
1128 - Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab
1129 - Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients
1142 - Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
1149 - Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
1172 - Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center
2037 - Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial
2041 - R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET
2042 - Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial
2058 - Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma
2119 - Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy
2128 - Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
2357 - Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma
3038 - Real World Outcomes of Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy: An Updated Analysis
3046 - Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival
3063 - The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)
3308 - Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies

Natalino, F.

2124 - IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study

Natarajan, R.

3285 - Safety and Tolerability of Intra-Venous Ascorbic Acid in Allogeneic Hematopoietic Cell Transplant Recipients: A Matched Historical Control Study

Nataranjan, P.

2746 - Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients

Nath, K.

642 - Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma

Nath, L.

3303 - Alemtuzumab Versus Anti-Thymocyte Globulin As Conditioning Method for Allogenic Hematopoietic Stem Cell Transplant; A Meta-Analysis

Nath, R.

129 - Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
135 - High Doses of Targeted Radiation with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
193 - Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Nath, R.

1408 - HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Nathan, D. I.

2573 - Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

Nathan, P.

708 - Outcome Among Adolescents and Young Adults with Mature B-Cell Non Hodgkin Lymphoma at Pediatric Versus Adult Centers: A Population-Based Study Using the IMPACT Cohort

Nathan, R.

2582 - Ker-050, a Modified Actriia Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies
2736 - Ker-050, a Novel Inhibitor of Tgfβ Superfamily Signaling, Induces Red Blood Cell Production By Promoting Multiple Stages of Erythroid Differentiation

Nathan, S.

1210 - Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Nathanson, K. L.

952 - Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Nathens, A.

905 - Fiirst-2: Prospective, Randomized Study Comparing Administration of Clotting Factor Concentrates with Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients

Nathwani, N.

549 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
3243 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Natkunam, Y.

281 - Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage
556 - CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering
736 - CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Natsoulis, G.

51 - A Phase 2 Study of the LSD1 Inhibitor IMG7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Natsuhara, K.

2352 - Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Nattam, S.

1189 - Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas

Nauffal, M.

2371 - Defibrotide: Real World Experience for Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplantation

Nauffel, M.

587 - Orthopedic Toxicity Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials

Naumenko, S.

1986 - Mechanisms of Leukemia Stem Cell Plasticity Revealed By Single Cell Analysis

Nautiyal, J.

1908 - The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Nava, I.

1693 - Microcytosis in Erythropoietic Protoporphyria

Navada, S. C.

3107 - T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG
3114 - Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Navarrete, N.

566 - Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse
3263 - Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment

Navarro, A.

350 - The IGLV3-21^R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome
1104 - Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

Navarro, B.

2972 - Nodal Peripheral T-Cell Lymphoma with T Follicular-Helper Phenotype: A Different Entity? Results of the Spanish Retrospective Real-T Study

Navarro, G.

2358 - Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Navarro, R.

654 - Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Navarro, S.

674 - Gene Therapy for Fanconi Anemia, Complementation Group a: Updated Results from Ongoing Global Clinical Studies of RP-L102
2446 - Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Navarro, W.

1658 - Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease
2551 - A Multicenter, Multicohort, Open-Label, Single-Arm per Cohort, Phase II Study to Assess the Efficacy and Safety of Tabelecleucel in Patients with EBV-Associated Diseases Using an Adaptive Two-Stage Study Design
2554 - Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein-Barr Virus Viremia

Navas, B.

2805 - Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Naveed, K.

863 - A Retrospective Cohort Study Evaluating the Safety and Efficacy of Peri-Partum Tranexamic Acid for Women with Inherited Bleeding Disorders

Naves, A.

2972 - Nodal Peripheral T-Cell Lymphoma with T Follicular-Helper Phenotype: A Different Entity? Results of the Spanish Retrospective Real-T Study

Navin, N.

2897 - Mapping the Architecture of Adverse Risk AML Using Single-Cell RNA Sequencing

Navsaria, L.

1129 - Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients
1138 - Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma
2058 - Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma

Nawaz, N.

2965 - AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Naya, D.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Nayak, L. V.

202 - Performance of Khorana Score to Predict One-Year Risk of Venous Thromboembolism in over Two Million Patients with Cancer
442 - Prior History of Venous Thromboembolism Is a Significant Risk Factor for Recurrence of Thrombosis after Cancer Diagnosis
815 - Nanoparticle-Directed Targeting of Clustered PSGL-1 Mitigates Neutrophil-Derived Thrombosis in Antiphospholipid Antibody Syndrome
- NLF-2, Cancer, and Thrombosis
- Live Q&A

Nayak, L.

1024 - Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study
2372 - Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Haematopoietic Stem Cell Transplant
2400 - Real World Experience of Etanercept in Steroid Refractory Acute Graft Versus Host Disease from a Tertiary Cancer Centre in India
3327 - Comparison of Outcomes of Donor Lymphocyte Infusions with or without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic Transplant

Nayak, S.

1789 - Peak Thrombin and D-Dimer Levels in Subjects with Severe Hemophilia Receiving Acute Treatment for Bleeding Episodes Experienced during Prophylactic Marstacimab Treatment

Naylor-Adamson, L.

1748 - Bruton's Tyrosine Kinase Inhibitors Impair Fcγriia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria

Nazarewicz, P.

209 - The Impact of Race and Ethnicity on Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Nazeer, T.

2961 - Observations of PET Scan Levels of Standard Uptake Values (SUV) in Low Grade Follicular Lymphoma (LGFL) with High Proliferation Index (HPI)

Nazha, A.

34 - The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia
541 - A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes
655 - Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)
1850 - TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity
1923 - SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial
1962 - A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia
2879 - The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia
2884 - Molecular Dissection of Normal Karyotype Acute Myeloid Leukemia
3381 - Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence
3383 - Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

Ndiaye, A. P.

1399 - A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma
1513 - Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma
2309 - Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Ndonwi, M.

407 - Mutant TRP53-R172H Has Gain-of-Function or Dominant-Negative Effects in Response to Different Hematopoietic Stressors in Mice

Nduba, V.

1716 - Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Neal, A.

1599 - Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma

Neal, E.

2041 - R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Neal, M. D.

517 - Reduced Cleavage of Von Willebrand Factor By ADAMTS13 Exacerbates Acute Kidney Injury Secondary to Traumatic Injury
- Session Introduction
- Live Q&A and Panel Discussion

Neale, A.

22 - Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

Nebbioso, M.

3411 - Multi-Parameter Neurological Study Based on Combined Conventional and Functional Assessments in Gaucher Disease Patients (SENOPRO_GAUCHER Study)

Nebor, D.

1706 - Rheological Impact of GBT1118 Cessation in a Sickle Mouse Model

Nechesnuyk, A.

3299 - Total Body Irradiation Among Recipients of Tcrαβ /CD19- Depleted Grafts in a Cohort of Children with Hematologic Malignances: Single Center Experience

Nechiporuk, T.

261 - Evolution of Gilteritinib Resistance from Residual Disease to Relapse
567 - A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Nedelcu, V.

3462 - Assessment of Hematologic and Coagulation Parameters As Predictive Value in COVID-19 with Unfavourable Evolution

Nedumaran, P.

1103 - Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

Neelapu, S. S.

405 - Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
485 - Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma
645 - A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
700 - Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
1128 - Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab
1172 - Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center
1187 - Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
2036 - Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
2042 - Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial
2055 - A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM)
2100 - Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
2103 - ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
2119 - Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy
2128 - Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
3046 - Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival
3063 - The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Neely, J. J.

1131 - Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma

Nefedova, Y.

1416 - A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

Neff, T.

749 - Pooled Efficacy and Cardiovascular Safety Results of Roxadustat Compared with Epoetin Alfa in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
1671 - Pooled Efficacy and Cardiovascular Analysis of Roxadustat Compared with Placebo in Anemia Correction in Chronic Kidney Disease Patients Not on Dialysis

Negre, O.

2447 - Multiplex CRISPR/Cas9 Genome Editing Targeting the BCL11A/HBG Axis Maximizes Fetal Hemoglobin Reinduction but Generates Chromosomal Translocations Which Persist In Vivo

Negri Aranguren, P.

1159 - Risk-Adapted Therapy with ABVD for Low- and Intermediate-Risk Patients and Oepa-Copdac for High Risk Patients Plus Involved-Field Radiation Therapy (IFRT) Based on Prognosis at Diagnosis and Early Response: Results from Pediatric Argentinian Collaborative Group Gatla Study for Children and Adolescents with Hodgkin Lymphoma

Negricea, R.

702 - Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
1184 - Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Négrier, C.

511 - Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors – Results from the Phase II Study
1800 - Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4)
2693 - Longitudinal Assessment of Thrombin Generation in Patients with Hemophilia Receiving Fitusiran Prophylaxis: Phase II Study Results

Negrin, R. S.

354 - Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants
495 - Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis
736 - CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
975 - Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study
1507 - Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma
1788 - Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity
2329 - RNA and TCR Sequencing Shed Light on Mechanisms of Treg Suppression in a Murine Model of Acute GvHD
3255 - Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet
3322 - Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant
3332 - Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation

Nehme, S. A.

3488 - Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment

Neil, Z. A.

513 - Incidence of Pulmonary Embolus after Catheter Removal in Children with Central Venous Catheter Related Venous Thromboembolism: A Report from the CHAT Consortium
3396 - Development and Validation of a Computable Phenotype for Bleeding in Hospitalized Patients: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study

Neill, L.

1016 - Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme
3274 - Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

Nejad, P.

2900 - Longitudinal Molecular Profiling in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Nejati, R.

1173 - A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families

Nekhai, S.

792 - Mass-Spectrometry Analysis of Urinary Biomarkers of Endothelial Injury in Sickle Cell Anemia Patients
1710 - Genetic Association of Clinical Complications for Genes Differentially Expressed in Reticulocytes of Sickle Cell Anemia
1821 - Alkaline Phosphatase Is Associated with Red Cell Alloimmunization in the Pulmonary Hypertension and Hypoxic Response (PUSH) Sickle Cell Disease Cohort
2597 - Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts
2633 - Use of Multiple Urinary Biomarkers for Early Detection of Chronic Kidney Disease in Sickle Cell Anemia Patients
2653 - Interferon Induction By HbS, SERINC5 Upregulation and Reduction of HIV-1 Nef and AP2 Contribute to HIV-1 Restriction in Sickle Cell Disease
- Urinary Proteomics and Sickle Nephropathy
- Exploring the ‘Omics of Cardiovascular and Renal Sequelae of SCD- Live Q&A and Panel Discussion

Nelanuthala, S.

2882 - Hyperglycemia Cooperates with Tet2 Heterozygosity to Induce Leukemia Driven By Pro-Inflammatory Cytokine Induced Lncrna Morrbid

Nellenbach, K. A.

629 - Differential Sialic Acid Content in Adult and Neonatal Fibrinogen Mediate Differences in Clot Polymerization

Nellesen, D.

2064 - Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials
3459 - A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

Nelson, A. R.

126 - A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter’s Transformation and De Novo Diffuse Large B-Cell Lymphoma

Nelson, B. H.

639 - The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma
1118 - Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma

Nelson, B. H.

2931 - Single Cell Profiling Reveals Unique CXCL13 Positive T Cell Subsets in the Tumor Microenvironment of Lymphocyte Rich Classic Hodgkin Lymphoma

Nelson, C.

- How to Diagnose and Manage SAMD9 and SAMD9L Syndromes?
- Live Q&A
- Session Summary and Live Q&A

Nelson, J.

2503 - Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL)

Nelson, J. A.

2080 - Clinical Characteristics and Follow-up Post-Surgery of Women with Bia-ALCL Operated at a Single Institution

Nelson, K. M.

1476 - Isavuconazonium Sulfate Use in Multi-Modal Management of Invasive Zygomycosis in Four Pediatric Allogeneic Hematopoietic Cell Transplant Patients

Nelson, M.

2473 - Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment

Nelson, M.

739 - Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses

Nelson, M. D.

2706 - Hemodynamic and Ventilatory Responses during Exercise in Pediatric Patients with Pulmonary Embolism

Nelson, N. E.

597 - Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study
3037 - Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance

Nelson, S. C.

2632 - Late Splenic Sequestration: A Consequence of Early Hydroxyurea Use?

Nelson, V.

1190 - A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen
3031 - Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Nemchenko, I.

3073 - The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

Nemecek, E. R.

419 - Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Nemeth, E.

219 - Transgenic Mice Overexpressing Erythroferrone, a Novel Erythrokine, Develop Iron Overload and Multi-Organ Iron-Independent Abnormalities
767 - Iron-Dependent Apoptosis Causes Embryotoxicity in Inflamed and Obese Pregnancy
773 - Hepcidin and Erythroferrone Levels in p.C282Y Homozygotes and Control Subjects in the HEIRS Study
1692 - Maternal Hepcidin Suppression Is Essential for Healthy Pregnancy
2592 - Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis
2594 - Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models
2596 - Compared to Normal-Weight Pregnant Women, Overweight Pregnant Women Fail to Upregulate Iron Absorption in the Third Trimester Despite Iron Deficiency and Their Infants Are Born with Lower Body Iron Stores

Nemets, A.

727 - A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Neo, E.

1465 - High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients : A Multicenter Study in Singapore

Neparidze, N.

308 - Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes
728 - A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)
1669 - Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia
3173 - Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Nephew, K.

2882 - Hyperglycemia Cooperates with Tet2 Heterozygosity to Induce Leukemia Driven By Pro-Inflammatory Cytokine Induced Lncrna Morrbid

Neppalli, A. K.

3480 - Efficacy, Safety and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma: A Single Center Experience

Neptune-Buon, M.

1362 - A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma
2247 - ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application

Neri, A.

60 - Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma
490 - FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom’s Macroglobulinemia By Silencing MYD88
2270 - RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma
3142 - Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas’

Neri, P.

719 - Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy
SCI-40 - Immune Deregulation in Active Multiple Myeloma

Nero, A. C.

17 - Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU
801 - An Age Analysis of the International Sickle Cell World Assessment Survey (SWAY), Focusing on Symptoms, Treatment Goals and the Impact of SCD on Patients’ Daily Lives
808 - Symptoms and Complications of Sickle Cell Disease Analyzed By Patient-Reported Genotype, Sex and Country/Region: Results from the International Sickle Cell World Assessment Survey (SWAY)

Nersesyan, K.

2300 - Population-Level Projections for Multiple Myeloma Patients By Line of Therapy in the USA

Ness, D.

2095 - The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells In Vitro

Neto, J. V.

1604 - Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Neubauer, A.

458 - Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
2807 - Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Neuberg, D. S.

586 - Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001
659 - Multiplexed CRISPR In Vivo Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter’s Syndrome
1304 - IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia
1911 - Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy

Neuberg, D. S.

170 - Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings
215 - Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
579 - Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
660 - The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL
662 - Expression of Sf3b1-K700E accelerates the Development of Chronic Lymphocytic Leukemia in a Del(13q) Murine Model
941 - RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model
1261 - Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults
1297 - Genetic Determinants and Evolutionary History of Richter's Syndrome
1728 - Impact of Sickle Cell Trait on Morbidity and Mortality from Sars-Cov-2 Infection
1935 - Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults
1952 - A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies
1955 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults
2208 - Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia
2433 - Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation
2810 - Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
2856 - Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial

Neuenburg, J. K.

2938 - Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Neuenkirchen, N.

410 - High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies

Neufeld, E. J.

Neugebauer, K. M.

410 - High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies

Neuman, L.

1795 - The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptocog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with Inhibitors

Neuman, R.

470 - Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Neumann, D.

3015 - Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Neumann, M.

395 - Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols
2910 - Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols

Neumayr, L. D.

1574 - Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease
1730 - The Grndad Registry: Contemporary Natural History Data and an Analysis of Real-World Patterns of Use and Limitations of Disease Modifying Therapy in Adults with SCD
2616 - Differential Acetone Extraction of Total and Hemoprotein-Unbound Heme to Quantify Heme Binding Capacity of Plasma in Patients with Sickle Cell Disease: The Role of Heme Scavengers

Neumeister, P.

359 - Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial
3027 - Phase II Single-Arm “Window-of-Opportunity” Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) – First Results of the AGMT NHL15B Study

Neunert, C.

150 - Decision Aid to Support Shared Decision Making in Pediatric Refractory Immune Thrombocytopenia
- Health Outcome Disparities in Pediatric Benign Hematology
- Live Q&A and Panel Discussion

Neupane, K.

1029 - Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review
2313 - Maintenance Therapy in Newly Diagnosed and Transplant Ineligible Multiple Myeloma Patients: A Meta-Analysis
2373 - Efficacy and Safety of Recombinant Thrombombomodulin for the Prophylaxis of Vaso-Occlusive Complications in Allogenic Hematopoietic Stem Cell Transplantation : A Systematic Review and Meta-Analysis
2382 - Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review
2593 - Efficacy and Safety of Amlodipine in Preventing Myocardial Iron Overload in Patients with Transfusion-Dependent Thalassemia Major : A Systematic Review and Meta-Analysis

Nevala, W. K.

1430 - Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models

Neven, B.

822 - Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up

Neviani, V.

2836 - Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Nevill, T. J.

1280 - MDS Iron Road: An Internet-Based Algorithm for the Diagnosis, Workup and Management of Iron Overload (IOL) in Patients with Myelodysplastic Syndromes (MDS) from the Canadian Consortium on MDS (CCMDS)
1291 - Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study
2197 - High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS

Neville, K.

13 - Randomized Controlled Trial of Fixed Low-Vs Moderate-Dose Hydroxyurea for Primary Stroke Prevention in Sub-Saharan Africa: Final Results of the Spring Trial

Newberg, J.

1102 - Genomic Ancestry in B Cell Lymphoid Malignancies

Newby, G. A.

673 - Base Editing Eliminates the Sickle Cell Mutation and Pathology in Hematopoietic Stem Cells Derived Erythroid Cells
3367 - Adenosine Base Editing of γ-Globin Promoters Induces Fetal Hemoglobin and Inhibit Erythroid Sickling

Newcomb, J.

1363 - TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Newcombe, A.

522 - A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Newell, L. F.

635 - Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders
3346 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Newland, A.

1757 - Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Newman, K. A.

2714 - A Low Dose Heparinized Saline Protocol Is Associated with Improved Duration of Arterial Line Patency in Critically Ill COVID-19 Patients

Newman, P. J.

1835 - Conditional CRISPR-Mediated Deletion of Lyn Kinase Promotes Megakaryocyte Differentiation, Platelet Production and Function

Newsam, A. D.

2092 - R-Nanochop Incorporating a TFR1-Targeted Doxorubicin Nanocarrier Is Superior to R-CHOP in a PDX Model of Diffuse Large B-Cell Lymphoma

Neylon, A.

2289 - Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Soft-Tissue Plasmacytomas: Icaria-MM Subgroup Analysis

Ng, B.

419 - Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Ng, C. T.

418 - Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab
827 - Impact of Itolizumab on the Expression of CD6 and the Function of Effector T Cells

Ng, E.

2200 - Implementation of Flow Cytometric Monocyte Repartition Assay for Assessment of Chronic Myelomonocytic Leukaemia (CMML) in Bone Marrow

Ng, H. J.

879 - Thrombotic Events in COVID-19 Patients and Its Comparison with Other Non-Sars-Cov-2 Respiratory Viruses
3026 - Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Ng, I. M.

879 - Thrombotic Events in COVID-19 Patients and Its Comparison with Other Non-Sars-Cov-2 Respiratory Viruses

Ng, L. G.

9 - A Novel Lncrna, Lncery, Interacts with Wdr82 to Regulate Erythroid Differentiation By Promoting Globin Gene Transcription
450 - In Situ Fate Mapping of Native and Stress Myelopoiesis Reveals a Unique Niche for Mono- and Dendritic Cell –Poiesis

Ng, L.

3026 - Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Ng, N.

3469 - Reducing Time to Chemotherapy Administration in the Outpatient Setting of a Tertiary Cancer Centre Using a Design Thinking Approach

Ng, P. P.

95 - The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

Ng, S.

531 - Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma
2216 - Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Ng, S. Y.

2936 - Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy

Ng, S. B.

2916 - Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer⁄T Cell Lymphoma

Ng, S. W.

1989 - Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Ng, T. F.

1556 - Detection of Del(17p) in Hematological Malignancies By Imaging Flow Cytometry

Ngo, D.

991 - Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)
1470 - Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis

Ngo, E.

3469 - Reducing Time to Chemotherapy Administration in the Outpatient Setting of a Tertiary Cancer Centre Using a Design Thinking Approach

Ngo, E.

2479 - Maximising Capacity and Saving Cost in an Outpatient Chemotherapy Centre during a Pandemic: A Quality Improvement Project

Ngo, S.

785 - Validation of a Predictive Score of Acute Chest Syndrome (presev-2 study) in Adults

Nguyen, A.

225 - Palmitoylethanolamide-Mediated Inhibition of Nogo-a Signaling Attenuates Pain in Sickle Mice
3098 - Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2^V617+ MPN Thrombosis

Nguyen, A.

2367 - A First-in-Human Study of MAU868, a Novel Neutralizing Antibody Against BK Virus

Nguyen, A.

1598 - Healthcare Resource Utilization and Cost of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma Receiving the BCMA-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Trial
2514 - Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

Nguyen, B.

3376 - PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Nguyen, C.

2526 - Geographic Disparities of Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients in Virginia

Nguyen, C.

1416 - A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

Nguyen, C. L.

730 - TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response

Nguyen, C.

566 - Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse
1434 - Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor
3263 - Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment

Nguyen, D. T.

523 - Transcriptional Control of HP1a By the RNA Binding Proteins Rbmx/L1 Maintain Chromatin State in Myeloid Leukemia

Nguyen, D. D.

2870 - Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Nguyen, D.

1972 - Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML
3258 - Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar T^TM Cell Therapy for the Treatment of Multiple Myeloma

Nguyen, E.

3003 - Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Nguyen, H. V.

2493 - Patient Adherence to Medication within a New Multidisciplinary Thrombosis Service

Nguyen, H. H.

2366 - Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Nguyen, J.

2609 - Microvascular Stasis Inhibition By Hemopexin in the Townes Mouse Model of Sickle Cell Disease
3098 - Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2^V617+ MPN Thrombosis

Nguyen, K.

1071 - Best Practices for Validation of Measurable Residual Disease Assessments By Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia

Nguyen, L. X. T.

710 - Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC)
2872 - Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo

Nguyen, M. A. T.

258 - Clonal Hematopoiesis By HLA Class I Allele-Lacking Hematopoietic Stem Cells and Concomitant Aberrant Stem Cells Is Rarely Associated with Clonal Evolution to Secondary Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Acquired Aplastic Anemia

Nguyen, M.

714 - Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms

Nguyen, M.

2592 - Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis

Nguyen, N. K.

2904 - An Ara-C, Daunorubicin, and Etoposide microRNA (ADEmiR) Score As a Prognostic Tool to Predict AML Treatment Outcomes

Nguyen, N.

2733 - Prdm16 Is a Critical Regulator of Adult Long-Term Hematopoietic Stem Cell Quiescence

Nguyen, N.

2852 - Real World Outcomes of Liposomal Daunorubicin and Cytarabine Versus 7+3 in Patients with Secondary Acute Myeloid Leukemia

Nguyen, P.

1967 - Multi-Omic Based Antigen Discovery for the Immunotherapy of Pediatric Acute T Cell Lymphoblastic Leukemia

Nguyen, P. H.

951 - The Scaffolding Protein NEDD9 Regulates Chronic Lymphocytic Leukemia Cell Migration Via the CXCR4 - CXCL12 Axis and Promotes Disease Progression

Nguyen, P. L.

1284 - Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study
3123 - Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

Nguyen, S.

1690 - DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin
2599 - DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia

Nguyen, T.

264 - BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
524 - High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Nguyen, T. T.

2626 - Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Nguyen, T. V.

724 - First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
1358 - Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001
1359 - Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations

Nguyen, U.

591 - Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Nguyen-Cao, M.

2159 - Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Nguyen-Khac, F.

3126 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Ngwube, A. I.

139 - Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Nibber, N.

1871 - The RNA Binding Protein IGF2BP3 Is Required for MLL-AF4 Mediated Leukemogenesis

Nichol, M. B.

2490 - Hematology Utilization Group Studies Part VII (HUGS VII): Costs and Impact of Disease in Older Persons with Hemophilia
2529 - Association between Aging and Health Status in Persons Living with Hemophilia and Controls without a Bleeding Disorder – Insights from the Probe Study
2530 - Depressive Disorders Among Adults with Hemophilia a
3401 - Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease
3457 - Impact of Hemophilia a Inhibitor on Joint Health and Health-Related Quality of Life from the Hemophilia Utilization Group Studies Part VIII in the U.S

Nicholas, C. A.

2273 - Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

Nicholas, J. A.

2655 - Platelet Membrane Procoagulation in Preeclampsia

Nicholas, P.

1849 - Towards Identifying the Target of Autoimmunity in Aplastic Anemia

Nicholls, A.

1938 - Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Nichols, C.

185 - Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases

Nichols, D.

1021 - CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Nichols, J.

681 - Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Nichols, K.

730 - TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response

Nichols, K. E.

317 - Germline Gain-of-Function JAK3 Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells

Nichols-Vinueza, D. X.

2388 - Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with GATA 2 Deficiency: Influence of Donor Stem Cell Source and Post-Transplantation Cyclophosphamide

Nicholson, E.

1016 - Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Nicholson, G.

1631 - Medically Attended Anxiety or Depression Is Increased Among Newly Diagnosed Patients with Cold Agglutinin Disease (CAD)

Nickel, R. S.

1824 - Impact of Universal Irradiation on Chronic Transfusion for Sickle Cell Disease

Nickerson, D. A.

231 - A Multi–Omics Approach to X-Chromosome Inactivation (XCI) Identifies Severe Xci Skewing in Female Genetic Carriers of Hemophilia

Nicolas, J. M.

833 - Circulating Biomarkers of COVID-19-Triggered Endotheliopathy: From Conjecture to Certainty

Nicolas-Virelizier, E.

1161 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Nicolas-Virelizier, E.

475 - PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study
3044 - Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma
3052 - Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Nicolet, D.

6 - Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)
1069 - Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)
1983 - Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis
2895 - Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy

Nicoletti, E.

674 - Gene Therapy for Fanconi Anemia, Complementation Group a: Updated Results from Ongoing Global Clinical Studies of RP-L102
675 - A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1
2446 - Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Nicolini, F. E.

647 - Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
652 - Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib
1237 - Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line
3072 - ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Nicolson, P. L.

2659 - Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP)

Niculae Badoiu, M.

3462 - Assessment of Hematologic and Coagulation Parameters As Predictive Value in COVID-19 with Unfavourable Evolution

Nie, D.

1083 - Fusion Gene Map of Acute Myeloid Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 400 Cases in a Single Center
2915 - Fusion Gene Map of Acute Lymphoblastic Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 350 Cases in a Single Center

Nie, D.

1099 - Classification and Quantification of Oncogenic Ikaros Isoforms in B Cell Precursor Acute Lymphoblastic Leukemia By RNA-Seq
1883 - NGS-Based Screening to Comprehensively Decipher TKIs Resistant Mutations in BCR-ABL1 Positive Leukemias
2816 - Fanconi Anemia Gene Associated Germline Predisposition in Aplastic Anemia and Hematologic Malignancies

Nie, D.

2405 - Prophylactic Donor Lymphocyte Infusion Based on Two Different Time for Preventing Relapse in Advanced Acute Leukemia Undergoing Allo-HSCT: Comparison of Two Independent Prospective Cohorts

Nieborowska-Skorska, M.

1052 - TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Nieder, M.

355 - Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Niederweiser, D.

1522 - Clinical Relevance of Morphologic and Molecular Complete Remission in AML Patients Undergoing Reduced Intensity or Non-Myeloablative Conditioning

Niederwieser, D.

53 - Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
346 - Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients
347 - Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat
391 - Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603)
1252 - The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10⁹/L to < 100 × 10⁹/L) at Baseline
1283 - Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study
1519 - Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study
2431 - Prognostic Impact of Nutritional Status at Diagnosis and Weight Changes in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
3084 - Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple-Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi)
3088 - Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Nielsen, J. S.

639 - The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Nielsen, L. K.

3217 - Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Nielsen, T. G.

1124 - Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma
1203 - Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients
1208 - Risk Profiling of De Novo DLBCL Patients By Measuring Circulating Tumor DNA
1219 - Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study
2122 - A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL
2928 - Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma
2930 - The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World
3035 - TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making

Nieman, M. T.

- Leading Yourself

Niemann, C. U.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Niemann, C. U.

122 - Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible
2038 - Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Niemann, D.

458 - Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Niemeyer, C. M.

215 - Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
255 - RPA1 Gain of Function Causes Human Short Telomere Syndrome with Revertant Somatic Mosaicism
2181 - NF1 Tumor Suppressor Gene Inactivation in Juvenile Myelomonocytic Leukemia: New Genetic Evidence and Consequences for Diagnostic Work-up

Nierkens, S.

1100 - B-Cell Precursor Acute Lymphoblastic Leukemia Instructs Mesenchymal Stromal Cells to Alter Interferon-Related Gene Expression and Cyto/Chemokine Secretion

Niesman, M.

1314 - Early Results from a Phase 1 Dose Escalation Study Evaluating MS-553, a Novel, Selective Pkcβ Inhibitor, in Relapsed or Refractory CLL/SLL Patients

Niesvizky, R.

2362 - Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use
3423 - Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012–2017 Medicare Data

Nieto, Y.

189 - A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
472 - Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma
485 - Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma
531 - Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma
645 - A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
1172 - Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center
1453 - PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy
1506 - African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis
1511 - Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience
2390 - Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease
2413 - Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance
2422 - Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation
2423 - Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation
2983 - Association of Epstein–Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin’s Lymphoma
3063 - The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)
3331 - High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC)
3340 - Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma

Nieuwenhuis, E. E.

1856 - Untargeted Metabolomic Fingerprinting As a Potential Tool in the Diagnostic Evaluation of Diamond Blackfan Anemia

Nieves, R. M.

92 - Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia
243 - Genetic Basis of Erythrocyte Alloimmunization Among Children with Sickle Cell Anemia in the Dominican Republic
1705 - Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment

Niewisch, M. R.

928 - Disease Progression and Outcomes in Patients with Telomere Biology Disorders

Nifenecker, M.

1617 - Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect^® MDS/AML Disease Registry
2523 - Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect^® MDS/AML Disease Registry

Niggli, M.

1800 - Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4)

Niida, A.

385 - Combined Landscape of Gene Mutations and Copy Number Alterations in Clonal Hematopoiesis: Analysis in 10,612 Japanese Individuals

Niinimäki, R.

585 - The Association between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in the NOPHO ALL2008 Protocol

Niittyvuopio, R.

2437 - Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis
2438 - Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party

Nikiforov, A.

951 - The Scaffolding Protein NEDD9 Regulates Chronic Lymphocytic Leukemia Cell Migration Via the CXCR4 - CXCL12 Axis and Promotes Disease Progression

Nikiforow, S.

66 - Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial
418 - Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab
1658 - Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease
1749 - A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies
2371 - Defibrotide: Real World Experience for Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplantation
3310 - Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution

Nikiforow, S.

80 - DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant
190 - Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies
1040 - A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Nikolaenko, L.

1180 - Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells
3041 - Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience

Nikolaou, P. E.

969 - Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging

Nikolova, Z.

2939 - Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Nikolovska-Coleska, Z.

943 - Investigating the Roles of the Yeats Domain in MLL-ENL Mediated Leukemogenesis

Nikom, D.

3093 - LSD1 Inhibitor CPI-482 Shows Efficacy and Prolongs Survival in Mouse Models of AML and Post-MPN AML in the Context of Constitutive JAK-STAT Pathway Activation

Nikowitz, J.

533 - Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Niktoreh, N.

1919 - Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group
2804 - Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Niland, J.

533 - Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Nilsson, B.

1337 - Characterization of Rare Germline Variants in Familial Multiple Myeloma

Nilsson, L.

2403 - Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B

Nimer, S.

2764 - The Baf Subunit Dpf2 Regulates Resolution of Inflammation By Controlling Macrophage Differentiation Transcription Factor Networks

Nimkar, N.

895 - Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
1637 - Clinical Course and Outcomes of Sickle Cell Disease Patients with COVID-19 at a New York Hospital
1811 - Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients

Nimmagadda, S. C.

1048 - Impeding DNA Repair Offers a Novel Possibility for Personalized Therapy in AML Patients, Who Are Carrier of the Growth Factor Independence 1 Variant “GFI1-36N”
1049 - AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Nimubona, S.

654 - Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Ning, B.

102 - COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients
313 - COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Ning, J.

390 - Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia
690 - Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy
1041 - Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response
2811 - Predictors of Outcomes in Adult AML with MLL Rearrangements

Ninomiya, H.

1855 - COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor–Naïve or –Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Ninomoto, J.

123 - Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Niolat, J.

1294 - The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Niparuck, P.

753 - C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials

Niro, A.

LBA-5 - ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Niroula, R.

530 - Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma
2853 - Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethlators for Acute Myeloid Leukemia

Niscola, P.

1584 - Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy

Nisenbaum, R.

424 - Suboptimal Screening for Iron Deficiency in Pregnancy in a High Resource Setting

Nishida, Y.

956 - Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Nishida, Y.

1880 - Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias
2468 - High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML
2775 - Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias
3375 - Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells

Nishihori, T.

355 - Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results
1428 - Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma
1451 - Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel
2202 - Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)
2426 - Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee
3357 - Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Nishikawa, E.

2757 - Diagnostic Whole Exome Sequencing for 166 Patients with Inherited Bone Marrow Failure Syndrome

Nishimori, H.

1681 - Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement
2579 - Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria
2588 - Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Nishimoto, M.

1532 - Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Nishimura, A.

2014 - Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity

Nishimura, J. I.

756 - Phase 3 Study of Danicopan, an Oral Complement Factor D Inhibitor, As Add-on Therapy to a C5 Inhibitor in Patients with Paroxysmal Nocturnal Hemoglobinuria with Clinically Evident Extravascular Hemolysis
1550 - An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
1682 - Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors
1854 - Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism – Experience from the Phase I/II COMPOSER Study
1855 - COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor–Naïve or –Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria
2587 - Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors

Nishimura, K.

1772 - Pharmacology and Pharmacokinetics of NXT007; Emicizumab-Based Engineered Fixa/Fx Bispecific Antibody with Improved Properties

Nishimura, T.

1851 - SATB1 Regulates GATA1 Protein Expression in Early Hematopoiesis and Is Deregulated in Diamond Blackfan Anemia

Nishinaka-Arai, Y.

1046 - Autophagy Inhibition Enhances CDK4/6 Inhibitor-Induced Apoptosis in t(8;21) Acute Myeloid Leukemia Cells

Nishio, N.

2757 - Diagnostic Whole Exome Sequencing for 166 Patients with Inherited Bone Marrow Failure Syndrome

Nishio, N.

162 - CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Niss, O.

680 - Early Results from a Phase 1/2 Study of Aru-1801 Gene Therapy for Sickle Cell Disease (SCD): Manufacturing Process Enhancements Improve Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant
797 - Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center’s Experience
1714 - Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia

Nissen, F.

147 - Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis
1793 - Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry
2532 - Problem Joints and Their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia a: CHESS Paediatrics and CHESS II
3449 - An Insight into the Impact of Hemophilia a on Daily Life According to Disease Severity: A Preliminary Analysis of the CHESS II Study

Niswonger, J.

1549 - The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Niu, A.

102 - COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients
313 - COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Niu, B.

1017 - A Feasibility and Safety Study of Non-Viral Genome Targeting Anti-CD19 CAR-T in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Niu, L.

3440 - Feasibility of a Decision Support Software to Aid in the Interpretation of Somatic Mutations Detected in Hematologic Malignancies

Niu, Q.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
2153 - Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Niu, T.

2290 - Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Niu, X.

2868 - Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Niu, X.

2597 - Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts

Nivarthi, H.

1266 - Co-Expression of JAK2-V617F and Calr-del52 In Vivo Enhances Myeloproliferative Phenotype in Mice and Does Not Influence Competitive Fitness of Hematopoietic Stem Cells
3096 - Ifnα Attenuates the Disease Phenotype and Extends Survival in Mouse Models of MPN

Nixdorf, D.

1938 - Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Nixon, M.

1333 - Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice

Niyongere, S.

1970 - Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
3487 - Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Nizamuddin, I.

2559 - Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience

Nizamuddin, R.

2078 - Patient-Specific Metabolism Assessed By Visceral Fat and Diabetes May Alter Prognosis in Relapsed/Refractory Hodgkin Lymphoma

Nizzoli, M. E.

341 - Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Njoku, F.

1583 - Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease
1718 - Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease
1721 - Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease
2621 - Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease

Nnebe-Agumadu, U.

1719 - Impact of Oral Arginine Therapy on Global Arginine Bioavailability in Nigerian Children with Sickle Cell Anemia and Vaso-Occlusive Pain

Noble-Orcutt, K.

2779 - JAK/STAT Inhibition Targets TP53 altered Primary Human Acute Myeloid Leukemia Stem Cells

Noboa, A.

1165 - Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
2968 - Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
3036 - COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study

Noelle, R.

2642 - VISTA Targeting Modulates Tumor-Infiltrating Myeloid Cells to Overcome Adaptive Resistance

Noesslinger, T.

359 - Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Noetzli, L.

318 - The Secreted Tyrosine Kinase Vlk Is Essential for Normal Platelet Activation and Thrombus Formation

Noga, S. J.

3200 - In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Nogai, A.

2288 - Updates from a Phase Ib Study of Isatuximab, Bortezomib and Dexamethasone Plus Cyclophosphamide or Lenalidomide in Transplant Ineligible Newly Diagnosed Multiple Myeloma

Nogami, A.

2342 - A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): “Double Arm” CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy

Nogami, K.

1781 - An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Nogueras González, G. M.

997 - Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort
1129 - Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients
1138 - Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma
1910 - Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies
2037 - Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial

Noh, Y. S.

998 - HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

Nolan, B.

509 - Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A
867 - Final Results of PUPs B-LONG Study: Evaluating Safety and Efficacy of rFIXFc in Previously Untreated Patients with Haemophilia B
873 - Similar Pattern of Increase in FIX Levels in Female Carriers and Males with Hemophilia B Leyden

Nolan, C.

1193 - Phase Ib Trial with Dose Expansion of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Patients with Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Nolfi-Donegan, D.

832 - Heme Induced Platelet Mitochondrial Oxidant Production Regulates Thrombospondin-1 Release from Platelets
2654 - HMGB1-Mediated Platelet Activation Is Independent of Platelet Mitochondrial Reactive Oxygen Species Generation

Nolte, F.

656 - Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
3109 - A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Noman, A.

1651 - Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Noman, H. M.

1049 - AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Nomdedeu, B.

536 - Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial
1274 - Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the “Sintra-REV” Clinical Trial

Nomdedeu, J. F.

986 - Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)
2763 - Germline GATA2 Mutations (R986Q and R398W) Inhibit Endothelial Development and Augment Myeloid Differentiation during Early Human Hematopoiesis

Nomie, K.

638 - Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma

Nomie, K.

1106 - Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Nomura, A.

1781 - An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Nonavinkere Srivatsan, S.

409 - Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

Nooka, A.

1325 - Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma
1417 - DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) – 1-Year Outcomes By Prior Therapies
1419 - DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
1514 - Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
1592 - Role of clonoSEQ^®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
1655 - Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison
2290 - Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor
2299 - Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
2325 - Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
3211 - Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma
3221 - Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
3224 - Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
3426 - Cost-Effectiveness of Implementing Clonoseq NGS-MRD Testing Using the Emory MRD Decision Protocol in Multiple Myeloma

Noonan, K.

3205 - Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

Noone, D.

147 - Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis
2529 - Association between Aging and Health Status in Persons Living with Hemophilia and Controls without a Bleeding Disorder – Insights from the Probe Study
3449 - An Insight into the Impact of Hemophilia a on Daily Life According to Disease Severity: A Preliminary Analysis of the CHESS II Study

Noor, M.

583 - Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Noorani, M.

1128 - Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab
2119 - Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy

Noori, S.

3156 - Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Nooruddin, Z.

209 - The Impact of Race and Ethnicity on Diffuse Large B-Cell Lymphoma (DLBCL) Outcomes within the Veterans Health Administration (VHA)

Noppeney, R.

458 - Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
1905 - Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Norasetthada, L.

3407 - Aplastic Anemia in Thailand: Incidence and Treatment Outcome from a Prospective Nationwide Population-Based Study

Nordin, H. B.

1269 - ZRSR1 Cooperates with ZRSR2 in Regulating Splicing of U12-Type Introns in Murine Hematopoietic Cells

Norek, S.

1388 - Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
1399 - A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma
1513 - Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Nörenberg, D.

1206 - Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Nørgaard, J. N.

3177 - Amino Acid-Based Fluciclovine PET/CT Detection of Multiple Myeloma

Norgren, N.

1088 - Genomic and Transcriptomic Characterization of Adult and Pediatric Relapsed Acute Myeloid Leukemia Reveals Novel Therapeutic Targets

Noriega Concepcion, V.

634 - Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Norin, S.

417 - ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Norkin, M.

254 - Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Norkin, M.

297 - Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative
2293 - HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—Age Subgroup Analysis of Elderly Patients
2321 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy—Subgroup Analysis
2564 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)—Analysis of Adverse Events Related to Hospitalizations
3214 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)—Subgroup Analysis
3237 - HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics—Subgroup Analysis
3335 - Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation
3477 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) — Health-Related Quality of Life (HRQoL) Analysis

Norman, A. D.

2497 - Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX)
3132 - Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Normant, E.

1130 - Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies

Norris, K.

1295 - Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Norris, R.

1018 - Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children’s Oncology Group Pilot Study

North, D.

494 - Peripheral Blood CD34⁺ Donor Chimerism Is Superior to CD3⁺ Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies

North, T. E.

11 - An Essential Role for the RNA Editor-Exonuclease Axis in Terminal Erythroid Differentiation
1986 - Mechanisms of Leukemia Stem Cell Plasticity Revealed By Single Cell Analysis
SCI-4 - Extrinsic Factors Governing Hematopoietic Stem Cell Development

Northfelt, D.

3416 - Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Norton, L.

387 - Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients
2746 - Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients

Norton, S.

2284 - Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Norum, J. H.

970 - Karonudib Has Potent Anti-Tumor Effects in Preclinical Models of B-Cell Lymphoma

Nosaka, K.

280 - Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma

Noseworthy, P. A.

3144 - Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL)

Nosswitz, M.

469 - In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Notarangelo, L.

1586 - Influenza Vaccination in Asplenia: Improving Quality of Care in Time of Coronavirus

Notarangelo, L. D.

2140 - Impaired Sars-Cov-2 Specific Antibody Responses in Patients Treated with Anti-CD20 Antibodies
2388 - Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with GATA 2 Deficiency: Influence of Donor Stem Cell Source and Post-Transplantation Cyclophosphamide
2651 - Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases

Notardonato, L. D.

1641 - Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race

Notarfranchi, L.

2245 - PD-L1/PD-1 Pattern of Distribution within Bone Marrow Microenvironment Cells in Patients with Smoldering Myeloma and Active Multiple Myeloma
2258 - Short-Term Risk for Progression in Patients with Smoldering Multiple Myeloma: The Impact of CD56 Expression

Notaro, R.

1685 - COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy

Notaro, R.

1686 - Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

Noto, A.

1319 - Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax

Noto, B.

3311 - Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for the Assessment of Acute Intestinal GvHD and Prediction of Response to Immunosuppressive Therapy

Nouadje, G.

1562 - Development of a Hydrashift 2/4 Isatuximab Assay to Mitigate Interference with Monoclonal Protein Detection on Immunofixation Electrophoresis in Vitro Diagnostic Tests in Multiple Myeloma

Noubouossie, D.

1828 - Caring for Patients with Sickle Cell Disease during a Pandemic: Continuing to Provide Automated Red Blood Cell Exchange Transfusions in Difficult Times

Noura, M.

1046 - Autophagy Inhibition Enhances CDK4/6 Inhibitor-Induced Apoptosis in t(8;21) Acute Myeloid Leukemia Cells

Nouraie, S. M.

228 - The T117S Variant of Cytochrome b5 Reductase 3 Increases the Risk for Ischemic Stroke with Enhanced Anemia in Mice with Sickle Cell Disease
506 - Exercise Induced Changes of Vital Signs in Adults with Sickle Cell Disease
809 - Long-Term Phosphodiesterase 5 Inhibitor Use Improves Symptoms in Patients with Pre-Capillary Pulmonary Hypertension of Sickle Cell Disease
2597 - Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts
2625 - The Impact of Hydroxyurea Use on Cognitive Functioning of Children with Sickle Cell Disease in Ghana

Nourigat-Mckay, C.

908 - Distinct Transcriptional Signatures Distinguish the Emergence of Multipotent Progenitors and Hematopoietic Stem Cells from Endothelial Precursors in the Murine Embryo

Novak, A. J.

534 - Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma
1117 - High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
2022 - Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment
2039 - Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era

Novak, J.

458 - Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
589 - Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine
1037 - Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naive Patients with Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Novakovic, V. A.

1752 - Cryopreserved Platelets Retain Agonist Responsiveness and Support for Factor VIII Function

Novakovskiy, G.

2868 - Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Novelli, E. M.

504 - Assessing Dynamic Cerebral Autoregulation in Patients with Sickle Cell Disease Using Near-Infrared Spectroscopy and Paced Breathing
2618 - Loss of FXR Signaling Promotes Chronic Liver Injury in Sickle Cell Disease
2625 - The Impact of Hydroxyurea Use on Cognitive Functioning of Children with Sickle Cell Disease in Ghana

Novichkova, G.

2646 - Nicotinamide (NA) Treatment Improves Response to G-CSF in Severe Congenital Neutropenia (SCN) Patients

Novick, S.

1418 - KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma
2323 - KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Novikova, L. V.

1696 - Regulation of GATA-1-Controlled Genes By O-Glcnacylation in Erythroid Cells

Novina, C. D.

2270 - RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Novis, Y.

194 - Disruption of the Oral Microbiota Predicts Poor Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
1490 - Long-Term Follow-up of Ruxolitinib in Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (GVHD)
1601 - Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL
2399 - Ikaros Expression in the Graft Is Associated with Chronic Graft Versus Host Disease
3286 - “Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose”
3293 - Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients

Noviski, M.

2788 - Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Novitzky-Basso, I. N.

463 - Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation
1234 - BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure
1247 - Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial
1498 - Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment
1530 - Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission
2396 - Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment
2428 - ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors
3316 - Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Novo, A.

634 - Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Novosad, O.

2106 - DA-EPOCH-R VS R-CHOP in Patients with Primary Mediastinal Large B-Cell Lymphoma: Results of Prospective Randomized Ukrainian Multicenter Study

Novotny, J.

1905 - Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Novotny, W.

2940 - Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial

Nowak, A.

922 - Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy
1844 - Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)

Nowak, E.

2642 - VISTA Targeting Modulates Tumor-Infiltrating Myeloid Cells to Overcome Adaptive Resistance

Nowakowski, G. S.

340 - Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R² Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
534 - Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma
703 - Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
1117 - High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
1123 - Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R² Followed By Maintenance
1141 - Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes
1192 - Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E
1210 - Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma
2056 - Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis
2097 - Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma
2112 - Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2945 - A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies
3028 - A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase
3150 - Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience

Nowakowski, K. E.

171 - Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair
2132 - The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma

Nowis, D.

2787 - Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Nowlin, A.

1727 - Healthcare Utilization Among Children and Adolescents with Sickle Cell Disease during the COVID-19 Pandemic

Noy, A.

470 - Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
1147 - CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population
1307 - MRD-Driven Time Limited Therapy with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Previously Untreated Chronic Lymphocytic Leukemia
2097 - Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma
2130 - Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

Noy, D.

2536 - Under-Diagnosed and Under-Treated Menorrhagia in Young Women Produce Suboptimal Performance

Noye, J.

3296 - Early Immunosuppressive Therapy for Idiopathic Pneumonia Syndrome Prior to Bronchoscopy Is Associated with Favourable Outcomes

Noyszewska-Kania, M.

2927 - SIRT1 and HSP90alpha Are Functionally Linked and Control Mitotic Chromosome Segregation and Cell Viability in a Subset of Dlbcls

Nozzoli, C.

2360 - On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Ntanasis-Stathopoulos, I.

1383 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis
2253 - The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma
2255 - A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias
2279 - Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study
2320 - The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents
3210 - IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Ntanasis-Stathopoulos, I.

3168 - A Simple and Robust Real-Time Quantitative PCR Method for the Detection of MYD88 L265P Mutation in Waldenström'smacroglobulinemia.

Ntanisian, K. I.

1763 - Immediate Pre-Splenectomy Platelet Count Predicts Splenectomy Response in Adult Immune Thrombocytopenia Patients

Nucci, F. M.

1240 - COVID-19 in Chronic Myeloid Leukemia Patients – Brazilian Experience
1604 - Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Nucci, M.

3286 - “Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose”
3293 - Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients

Nudel, M.

3126 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Nueesch, E.

3211 - Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Nugent, D. J.

1581 - Critical Telehealth and Healthcare Utilization during COVID-19 in Sickle Cell Disease: CBO Reach in Understanding the Patient Experience
2539 - Examining the Hemophilia Disability Paradox

Numan, Y.

262 - Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Numbenjapon, T.

753 - C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials

Numerof, R. P.

752 - Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study
838 - Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases

Nunes, A.

1081 - Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Nunes Gomes, C.

3289 - Citrulline Trajectory during Allogeneic Hematopoietic Stem Cell Transplantation Is Correlated to Conditioning Intensity and Non-Relapse Mortality

Nunez-Cruz, S.

1544 - Human Orthogonal IL-2/IL-2Rβ As a Tunable Approach to Enhance CD19-Specific CAR-T Cell Antitumor Activity

Nunez-Torron, C.

1063 - Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia
2883 - Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Nunns, G.

851 - Liver X Receptor (LXR) Is a Novel and Reversible Regulator of Trauma-Induced Coagulopathy

Nuno, K.

325 - Cytokine Rescue and Targeting of Inflammation-Sensitive RUNX1 Deficient Human CD34⁺ Hematopoietic Stem and Progenitor Cells
2765 - Multi-Omic Analysis Identifies Epigenetic Evolution in Relapsed Acute Myeloid Leukemia

Nur, E.

564 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)
1717 - Oxygen Gradient Ektacytometry-Derived Biomarkers Are Associated with the Occurrence of Cerebral Infarction, Acute Chest Syndrome and Vaso-Occlusive Crisis in Sickle Cell Disease

Nur, E.

17 - Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU
801 - An Age Analysis of the International Sickle Cell World Assessment Survey (SWAY), Focusing on Symptoms, Treatment Goals and the Impact of SCD on Patients’ Daily Lives
808 - Symptoms and Complications of Sickle Cell Disease Analyzed By Patient-Reported Genotype, Sex and Country/Region: Results from the International Sickle Cell World Assessment Survey (SWAY)

Nurmeev, I.

239 - Dabigatran Etexilate in Children with Venous Thromboembolism: Results of the Open-Label, Phase IIb/III, Randomized Diversity Clinical Trial

Nurmi, M.

3217 - Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Nuruddin, S.

3177 - Amino Acid-Based Fluciclovine PET/CT Detection of Multiple Myeloma

Nutescu, E. A.

1583 - Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease

Nutsch, H.

2955 - Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

Nuvolone, M.

1373 - The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis

Nuzhdina, E.

1106 - Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Nwabueze, C.

813 - A Clinician’s Experience in Initiation and Navigation of a Support Group for Sickle Cell Disease Patients – Can We Break Patient Bias?

Nwachukwu, C.

1624 - Outcomes in Vaso-Occlusive Crisis Treatment in the Emergency Department Vs. Acute Care Observation Center

Nwakanme, B.

464 - Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nwankwo, C.

304 - Mobile Health Use Predicts Self-Efficacy and Self-Management in Adolescents with Sickle Cell Disease
1574 - Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease

Nyamutswa, L.

1224 - The First Retrospective Commercial Claims-Based Analysis of CAR T Treated Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Nyffenegger, N.

782 - The Oral Ferroportin Inhibitor VIT-2763 Prevents Hemolysis and Vaso-Occlusion in a Sickle Cell Disease Model

Nyirenda, T.

1456 - Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Nysom, K.

1008 - Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial

Nzouakou, R.

785 - Validation of a Predictive Score of Acute Chest Syndrome (presev-2 study) in Adults

Author Index: N